The correlation between bone-specific response and outcome has already been explored in oncogene-addicted NSCLC, and osteoblastic reactions in patients treated with EGFR inhibitors have been associated with favorable outcomes (Pluquet et al. 2010). Here, EGFR is linked to non-small cell lung carcinoma.